CCM
SIOX

Camber Capital Management’s Sio Gene Therapies Inc. Common Stock SIOX Stock Holding History

Camber Capital Management’s Portfolio SIOX Stock Details SIOX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-125,000
Closed -$23.2M – 32
2017
Q2 		$23.2M Buy
+125,000
New +$21.9M 1.13% 25

Other funds holding SIOX

QF
QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PC
PointState Capital New York $7.9B AUM 42.31% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
IA
IPL Advisers New York $158M AUM 18.16% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return

Camber Capital Management's SIOX Position: Q3 2017 in Review

Camber Capital Management sold out of Sio Gene Therapies Inc. Common Stock (SIOX) in Q3 2017, closing a stake of 125,000 shares — an estimated $23.2M sold.

Camber Capital Management first reported a position in SIOX in Q2 2017 and held it in 1 quarter. The position peaked at $23.2M in Q2 2017. 114 funds tracked by Wall St. Rank hold SIOX as of Q3 2017.

  • Camber Capital Management reported no remaining Sio Gene Therapies Inc. Common Stock position as of Q3 2017 after selling out during the quarter.
  • Camber Capital Management sold 125,000 Sio Gene Therapies Inc. Common Stock shares in Q3 2017, an estimated $23.2M.
  • Camber Capital Management first reported a position in Sio Gene Therapies Inc. Common Stock in Q2 2017 and held it in 1 quarter.
  • Camber Capital Management's Sio Gene Therapies Inc. Common Stock position peaked at $23.2M in Q2 2017.
  • 114 funds tracked by Wall St. Rank held Sio Gene Therapies Inc. Common Stock as of Q3 2017.

Based on Camber Capital Management's 13F filing for Q3 2017, filed 14 Nov 2017.